About: Plasma levels of thioridazine and metabolites are influenced by the debrisoquin hydroxylation phenotype

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Plasma levels of thioridazine and metabolites are influenced by the debrisoquin hydroxylation phenotype Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 01 March 1991

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в березні 1991 (uk) article scientifique publié en 1991 (fr) artículu científicu espublizáu en marzu de 1991 (ast) im März 1991 veröffentlichter wissenschaftlicher Artikel (de) scientific article published on 01 March 1991 (en)
publication date	wds:Q70123367-E21CB88F-A868-46CC-AA84-E4FEE7B651B1
publication date	1991-03-01 00:00:00Z (xsd:dateTime)
author name string	wds:Q70123367-174BA52B-BE9A-499C-A71F-171E5C1E8668 wds:Q70123367-217E57F9-E4D7-4D05-940A-261E61BF99B7 wds:Q70123367-63D0E54C-EDEE-4771-B35A-C09075D43E27 wds:Q70123367-6B47A0B9-2B7C-471D-82F4-26A651B8265C wds:Q70123367-8E909652-7C37-47A4-8815-4715560138DC wds:Q70123367-9CE33C36-EF50-4DE9-88BF-27EE6DEB3205 wds:Q70123367-EA6F76A2-4A95-46DB-B8C4-481B786AC270 wds:Q70123367-EB4D1CE2-622A-4691-87C2-EFA5981D3735
author name string	H Ring M Hammarlund-Udenaes C Nordin A Lidén A Hedberg G Movin F Sjöqvist C von Bahr
rdfs:label	Plasma levels of thioridazine and metabolites are influenced by the debrisoquin hydroxylation phenotype (en) Plasma levels of thioridazine and metabolites are influenced by the debrisoquin hydroxylation phenotype (nl)
skos:prefLabel	Plasma levels of thioridazine and metabolites are influenced by the debrisoquin hydroxylation phenotype (en) Plasma levels of thioridazine and metabolites are influenced by the debrisoquin hydroxylation phenotype (nl)
name	Plasma levels of thioridazine and metabolites are influenced by the debrisoquin hydroxylation phenotype (en) Plasma levels of thioridazine and metabolites are influenced by the debrisoquin hydroxylation phenotype (nl)
title	wds:Q70123367-6A0EE258-3DF6-46B7-AC96-A9212FD7849B
title	Plasma levels of thioridazine and metabolites are influenced by the debrisoquin hydroxylation phenotype (en)
page(s)	wds:Q70123367-AD6C9820-4C70-4770-A6D8-F0D4A09078CA
page(s)	234-240
instance of	wds:Q70123367-57B3FC53-FA16-466C-9533-C08032E98D36
instance of	scholarly article
main subject	wds:Q70123367-A2804CE7-DB1A-4662-9801-3313D477CD99
main subject	phenotype
PubMed ID	wds:Q70123367-9A751E45-0679-4CAA-8337-1D463342161E
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/2007317
PubMed ID	2007317
published in	wds:Q70123367-DEFB4EE6-0DDD-4DEA-BF1D-47EFF5F883AD
published in	Clinical Pharmacology & Therapeutics
issue	wds:Q70123367-D5B16072-FB1E-4F4B-8F52-166E72DEEEC6
volume	wds:Q70123367-55E0B141-68BF-4E60-AF75-3B7E9C356BB5
issue	3
volume	49
DOI	wds:Q70123367-2D65925D-0B5E-4F05-9279-EABC8C0BB14E
DOI	http://dx.doi.org/10.1038/CLPT.1991.22
DOI	10.1038/CLPT.1991.22
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q70123367
is cites work of	Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions Polymorphic cytochromes P450 and drugs used in psychiatry Metabolism, pharmacogenetics, and metabolic drug-drug interactions of antipsychotic drugs Selective serotonin reuptake inhibitors and CNS drug interactions. A critical review of the evidence Pharmacokinetics and metabolism of thioridazine during co-administration of tricyclic antidepressants Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II. Pharmacogenetic aspects of drug-induced torsade de pointes: potential tool for improving clinical drug development and prescribing Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation Thioridazine: resurrection as an antimicrobial agent? Antipsychotics in older patients. A safety perspective The significance of QT interval in drug development Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation Cytochrome p450 phenotyping/genotyping in patients receiving antipsychotics: useful aid to prescribing? Disposition of clozapine in man: lack of association with debrisoquine and S-mephenytoin hydroxylation polymorphisms Chirality and drugs used in psychiatry: nice to know or need to know? Pharmacokinetic factors in the adverse cardiovascular effects of antipsychotic drugs P450 enzymes. Inhibition mechanisms, genetic regulation and effects of liver disease Population pharmacokinetics of nortriptyline during monotherapy and during concomitant treatment with drugs that inhibit CYP2D6--an evaluation with the nonparametric maximum likelihood method Plasma levels of the enantiomers of thioridazine, thioridazine 2-sulfoxide, thioridazine 2-sulfone, and thioridazine 5-sulfoxide in poor and extensive metabolizers of dextromethorphan and mephenytoin. Genetically determined adverse drug reactions involving metabolism Polymorphic debrisoquine oxidation and acute neuroleptic-induced adverse effects Clinically significant interactions of psychotropic agents with antipsychotic drugs Concentration-related pharmacodynamic effects of thioridazine and its metabolites in humans Cardiovascular adverse effects of antipsychotic drugs The influence of selective serotonin reuptake inhibitors on the plasma and brain pharmacokinetics of the simplest phenothiazine neuroleptic promazine in the rat. The influence of selective serotonin reuptake inhibitors (SSRIs) on the pharmacokinetics of thioridazine and its metabolites: in vivo and in vitro studies Paroxetine potentiates the central nervous system side effects of perphenazine: contribution of cytochrome P4502D6 inhibition in vivo. Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test Stereochemistry and drug efficacy and development: relevance of chirality to antidepressant and antipsychotic drugs Cytochrome P450 2D6 genotyping: potential role in improving treatment outcomes in psychiatric disorders Steady-state serum concentrations of the neuroleptic perphenazine in relation to CYP2D6 genetic polymorphism Failure to respond to treatment with typical antipsychotics is not associated with CYP2D6 ultrarapid hydroxylation. Contributions of ionic interactions and protein dynamics to cytochrome P450 2D6 (CYP2D6) substrate and inhibitor binding. Pharmacokinetic optimisation of the treatment of psychosis Pharmacokinetics of chlorpromazine and key metabolites Thioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotype Genetic polymorphism of drug metabolising enzymes in African populations: implications for the use of neuroleptics and antidepressants The molecular and enzyme kinetic basis for the diminished activity of the cytochrome P450 2D6.17 (CYP2D6.17) variant. Potential implications for CYP2D6 phenotyping studies and the clinical use of CYP2D6 substrate drugs in some African populations Pharmacokinetics of raclopride formulations. Influence of prolactin and tolerability in healthy male volunteers Comparison of the effects of thioridazine and mesoridazine on the QT interval in healthy adults after single oral doses. An introduction to enantiomers in psychopharmacology The metabolism of psychoactive drugs: a review of enzymatic biotransformation and inhibition Factors Affecting Drug Concentrations and QT Interval During Thioridazine Therapy The evaluation of thioridazine as a hematopoietic progenitor cell mobilizing agent in healthy human subjects Dextromethorphan O-demethylation polymorphism in Jordanians Torsades de pointes tachycardia induced by common cold compound medication containing chlorpheniramine

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 180 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software